Candida albicans is an opportunistic human fungal pathogen that causes lifethreatening systemic infections, as well as oral mucosal infections. Phospholipids are crucial for pathogenesis in C. albicans, as disruption of phosphatidylserine (PS) and phosphatidylethanolamine (PE) biosynthesis within the cytidine diphosphate diacylglycerol (CDP-DAG) pathway causes avirulence in a mouse model of systemic infection. The synthesis of PE by this pathway plays a crucial role in virulence, but it was unknown if downstream conversion of PE to phosphatidylcholine (PC) is required for pathogenicity. Therefore, the enzymes responsible for methylating PE to PC, Pem1 and Pem2, were disrupted. The resulting pem1 / pem2 / mutant was not less virulent in mice, but rather hypervirulent. Since the pem1 / pem2 / mutant accumulated PE, this led to the hypothesis that increased PE synthesis increases virulence. To test this, the alternative Kennedy pathway for PE/PC synthesis was exploited. This pathway makes PE and PC from exogenous ethanolamine and choline, respectively, using three enzymatic steps. In contrast to Saccharomyces cerevisiae, C. albicans was found to use one enzyme, Ept1, for the final enzymatic step (ethanolamine/cholinephosphotransferase) that generates both PE and PC. EPT1 was overexpressed, which resulted in increases in both PE and PC synthesis. Moreover, the EPT1 overexpression strain is hypervirulent in mice and causes them to succumb to system infection more rapidly than wild-type. In contrast, disruption of EPT1 causes loss of PE and PC synthesis by the Kennedy pathway, and decreased kidney fungal burden during the mouse systemic infection model, indicating a mild loss of virulence. In addition, the ept1 / mutant exhibits decreased cytotoxicity against oral epithelial cells in vitro, whereas the EPT1 overexpression strain exhibits increased cytotoxicity. Taken altogether, our data indicate that mutations that result in increased PE synthesis cause greater virulence and mutations that decrease PE synthesis attenuate virulence.
INTRODUCTION
Candida albicans is a fungus that typically resides as a commensal in the gastrointestinal tract of up to 70% of healthy individuals, as well as within the oral mucosa (Bouza and Munoz, 2008) . However, C. albicans can cause vaginal infections as well as opportunistic oral and systemic infections, which are more commonly seen in immunocompromised or immunosuppressed individuals (Kabir et al., 2012) . Systemic blood stream infections (BSIs) are of particular concern as they have mortality rates of approximately 30-50% (Williams and Lewis, 2011) , and Candida spp. are the fourth most common causes of BSIs in the United States (Kabir et al., 2012) . Treatment of systemic infections has encountered some limitations as a result of poor oral availability and high drug toxicity of some drugs (Letscher-Bru and Herbrecht, 2003; Mukherjee et al., 2005) . In addition, resistance to standard antifungal treatments such as fluconazole, by Candida spp., is an emerging issue (Sanguinetti et al., 2015) . It is therefore imperative that novel drug targets are discovered.
Phospholipid biosynthetic pathways are an attractive area to search for drug targets, as phospholipids are the major structural lipids that form cellular membranes (de Kroon et al., 2013) . Cells must therefore synthesize them from precursors acquired from their environment to support growth during infection. In addition to having a structural role within the cell, intermediate phospholipid metabolites can act as second messengers, and may therefore serve important regulatory functions (Exton, 1994; de Kroon et al., 2013) . As such, they are required for the growth and pathogenesis of C. albicans.
The most abundant phospholipids in C. albicans are phosphatidylglycerol (PG), cardiolipin (CL), phosphatidylserine (PS), phosphatidylethanolamine (PE), phosphatidylcholine (PC), and phosphatidylinositol (PI) (Singh et al., 2010; Cassilly et al., 2017) . The major biosynthetic pathway for the phospholipids PS, PE, and PC in C. albicans is known as the cytidinediphosphate diacylglycerol (CDP-DAG) pathway (Figure 1 ) (Henry et al., 2012) . Within this pathway, the common phospholipid precursor CDP-DAG is condensed with serine to form PS by the PS synthase Cho1 (Bae- Lee and Carman, 1984; Henry et al., 2012) . PS is then decarboxylated by one of two PS decarboxylases, Psd1 or Psd2, to form PE (Henry et al., 2012) . Based on work from S. cerevisiae, PE is predicted to be sequentially methylated by the PE methyltransferases Pem1 and Pem2 to form PC (Henry et al., 2012) .
Previously, our lab has demonstrated that the cho1 / and psd1 / psd2 / mutants are avirulent in the mouse model of systemic infection (Chen et al., 2010) . Interestingly, these mutants are avirulent despite having the ability to utilize an alternative phospholipid biosynthetic pathway known as the Kennedy pathway. This pathway uses exogenous ethanolamine or choline to synthesize PE or PC, respectively (Figure 1 ) (Gibellini and Smith, 2010) . We have recently reported that the Kennedy pathway alone cannot support virulence because the cho1 / and psd1 / psd2 / mutants cannot import FIGURE 1 | Model for yeast phosphatidylserine (PS), phosphatidylethanolamine (PE), and phosphatidylcholine (PC) biosynthesis. Proteins involved in CDP-DAG pathway mediated phospholipid biosynthesis are shown in purple, and those involved in Kennedy pathway mediated phospholipid biosynthesis are shown in blue. CDP-DAG, cytidine diphosphate diacylglycerol; MME, monomethyl phosphatidylethanolamine; DME, dimethyl-phosphatidylethanolamine; Etn, ethanolamine; Cho, choline; P-Etn, phosphoethanolamine; P-Cho, phosphocholine; CDP-Etn, cytidinediphosphoethanolamine; CDP-Cho, cytidinediphosphocholine.
sufficient ethanolamine from the host to support PE synthesis (Davis et al., 2018) . Growth of either mutant is restored in vitro in medium containing >100 µM ethanolamine, which is higher than the estimated concentration of ∼30 µM within the host (Houweling et al., 1992; Davis et al., 2018) . In addition, virulence is restored if PE synthesis is supported by heterologous expression of the Arabidopsis thaliana serine decarboxylase (AtSDC) (Davis et al., 2018) . This enzyme allows for decarboxylation of cytoplasmic serine to yield ethanolamine, which can be used to synthesize PE via the Kennedy pathway. Thus, AtSDC bypasses deficiencies due to importing low levels of exogenous ethanolamine (Davis et al., 2018) . Therefore, the wildtype fungus requires the CDP-DAG pathway to generate enough PE to cause disease since it cannot import enough ethanolamine to compensate for PE loss using the Kennedy pathway. Loss of PE synthesis should also impact downstream PC synthesis, and the impact of PC on virulence has been largely unstudied in this organism. In this study, we sought to determine if the loss of PC biosynthesis from the CDP-DAG pathway would attenuate virulence, or if the Kennedy pathway could compensate for this loss. In addition, we directly determined if Kennedy pathway mediated production of PE and/or PC is also important for virulence in C. albicans when the CDP-DAG pathway is still functional.
MATERIALS AND METHODS

Strains and Growth Media
Candida albicans strains used in this study were derived from the SC5314 background (Gillum et al., 1984) (Table 1) . Standard medium used for culturing C. albicans was YPD (1% yeast extract, 2% dextrose, and 2% peptone) and cultures were maintained aerobically at 30 • C in a shaking incubator at 225 RPM (Styles, 2002) . DH5-α Escherichia coli (NEB, C2987I) were used for plasmid construction (Table 2) , and were cultured in LB broth 
(1% tryptone, 1% NaCl, 0.5% yeast extract) in a rotating incubator at 37 • C (Guthrie and Fink, 2002 ).
Plasmid Construction
Primers described in this section are shown in Supplementary  Table S1 . The PEM1 knockout vector was created using the SAT1 flipper plasmid pSFS2A (Cat R ) (Reuss et al., 2004) . A 589 bp region of the PEM1 (CHO2/CR_02540W_A/orf19.169) 5 noncoding region (NCR) was amplified using the primers JCO197 and JCO198 which introduced KnpI and ApaI sites, respectively. This fragment was cloned into the KpnI and ApaI sites of pSFS2A. In addition, a 589 bp 3 NCR of PEM1 was amplified using JCO199 and JCO200, and was subsequently cloned into the SacII and SacI sites of pSFS2A to create the pYLC390 PEM1 knockout vector. In addition to the PEM1 knockout vector, a P MET3 repressible PEM1 expression vector was also created. To create this vector JCO165 and JCO166 were used to amplify an EcoRI-flanked SAT1-P MET3 fragment from pYLC229 (Chen et al., 2008) , which was subsequently cloned into the EcoRI site of a pBluescript SK+ plasmid to yield two isogenic clones: pYLC314 and pYLC315. The 5 NCR of PEM1 was amplified from genomic C. albicans DNA with JCO199 and JCO200 as a KpnI-ApaI fragment and cloned into pYLC315 (KpnI-ApaI) upstream of the SAT1 marked P MET3 promoter yielding pYLC410. To complete the construct, the PEM1 ORF was amplified along with the 3 NCR with JCO215 and JCO216, and this SacII-SacI fragment was cloned into pYLC410 downstream of the P MET3 promoter (SacII-SacI) to yield the PEM1 conditional expression vector pYLC414.
The SAT1 flipper vector pSFS2A was used to create a PEM2 knockout vector, pYLC388 (Reuss et al., 2004) . A 592 bp 5 NCR to PEM2 (OPI3/C3_06570C_A/orf19.7446) was amplified using JCO192 and JCO193 and cloned in the KpnI and ApaI sites of pSFS2A. A 587 bp NCR 3 to the PEM2 ORF was amplified using JCO194 and JCO195 and cloned into the SacII and SacI sites, resulting in pYLC388.
pYLC388 was used to create a reintegration construct for PEM2. The 5 NCR was released from pYLC388 by restriction with ApaI and KpnI. A 1,297 bp fragment including the PEM2 ORF (OPI3/C3_06570C_A/orf19.7446) and approximately 500 bp of NCR 5 to the ORF was amplified with BTO67 and JCO192. This fragment was subcloned into pYLC388 at the ApaI-KpnI sites to create pBT33.
The PEM1 reintegration construct was created using pSFS2A (Reuss et al., 2004) . pSFS2A was linearized using ApaI and XhoI. A 3451 bp fragment including approximately 500 bp of the 5 NCR of PEM1, the PEM1 ORF (CHO2/CR_02540W_A/orf19.169), and approximately 300 bp of the 3 NCR of PEM1 was amplified using BTO52 and BTO53 to introduce ApaI-XhoI sites, and subsequently was cloned into the linearized vector to create pBT47. pBT47 was linearized using NotI and SacI. A 622 bp NCR 3 to the PEM1 ORF (−356 to −978) was amplified using BTO54 and BTO55 to introduce NotI-SacI sites, and subsequently cloned into the linearized pBT47 vector to create the PEM1 reintegration vector, pBT49.
For the construction of an overexpression vector, pYLC314 was used. The P MET3 promoter was removed from pYLC314 by restriction with PstI, which flanks both sides of the insert. The constitutively active P ENO1 promoter, +928 to +1 5 of the ENO1 ORF (C1_08500C_A/orf19.395), was amplified from wild type C. albicans genomic DNA using the primers BTO30 and BTO31 to introduce BamHI and NotI sites, and was cloned into the BamHI and NotI sites of pYLC314 to create pBT1.
To overexpress EPT1, a 1,509 bp fragment including the EPT1 ORF (C7_02690C_A/orf19.3695) and approximately 300 bp of NCR 3 to the ORF was amplified from C. albicans genomic DNA using BTO35 and BTO36, and was cloned into the NotI and SacI sites of pBT1 to create the EPT1 overexpression vector, pBT11.
To create an EPT1 knockout vector, the 5 and 3 NCRs of the EPT1 ORF (C7_02690C_A/orf19.3695) were cloned into pSFS2A plasmid flanking the SAT1 flipper construct (Reuss et al., 2004) . First, a 471 bp fragment of the 5 NCR of the EPT1 ORF was amplified from C. albicans genomic DNA using BTO44 and BTO45 and subsequently cloned into the KpnI and XhoI sites of pSFS2A. In addition, a 494 bp fragment of the 3 NCR of EPT1 was amplified with BTO46 and BTO47 and cloned into the NotI and SacI sites to create pBT16.
To create an EPT1 reintegration construct a 2312 bp fragment including the EPT1 ORF, 903 bp 5 NCR of the EPT1 ORF, and 200 bp of the 3 NCR was amplified from genomic C. albicans DNA using TRO1044 and TRO1045. This PCR product was cloned into pSFS2A at the KpnI and XhoI sites to create pBT51. A 596 bp fragment of the 3 NCR (+202 to +798) was amplified from genomic DNA using TRO1046 and TRO1047 and cloned into the SacI and SacII sites of pBT51 to create the finalized EPT1 reintegration construct, pBT53.
Candida albicans Strain Construction
Plasmids were cut at the indicated restriction site(s) and linearized fragments were purified using the QIAquick PCR Purification Kit (QIAGEN, 28106) for single restriction digests, or the QIAquick Gel Extraction Kit (QIAGEN, 28704) if restriction digests resulted in multiple fragments. All Candida albicans transformations were performed via electroporation as described previously (Hasim et al., 2014) and plates containing 200 µg/mL nourseothricin (GoldBio, N-500-1) were used for selection of C. albicans transformants ( Table 1) . Following transformation, mutations were confirmed via PCR using the indicated primers (Supplementary Table S1 ).
To create the pem2 / strain, pYLC388 was linearized (KpnI, SacI) and transformed into wild type C. albicans (SC5314). The SAT1 marker was removed by FLP-mediated recombination from YLC393 using the SAT1 flipper method to create YLC400 (PEM2/pem2 ) (Reuss et al., 2004) . Linearized pYLC388 was again used to transform YLC400, which resulted in the pem2 / -SAT1 strain (YLC405). The SAT1 marker was removed by recombination from YLC405 to create YLC406 (pem2 / ).
YLC406 was transformed with a linearized pYLC390 fragment (KpnI, SacI) to create the PEM1/pem1 -SAT1 pem2 / mutant BTY38. The SAT1 marker was removed by recombination to create BTY66 (PEM1/pem1 pem2 / ). BTY66 was again transformed with linearized pYLC390 (KpnI, SacI) to create a pem1 / -SAT1 pem2 / mutant (BTY72), and the SAT1 marker was removed by recombination to create BTY77 (pem1 / pem2 / ).
To reintegrate PEM1 and PEM2 into the homozygous double mutant, pBT33 was linearized (KpnI, SacI) and transformed into BTY77 to create a pem1 / pem2 /pem2 ::PEM2-SAT1 strain, BTY138. The SAT1 marker was removed by recombination from BTY138, resulting in BTY147 (pem1 / pem2 /pem2 ::PEM2). BTY147 was transformed with linearized pBT49 (ApaI, SacI) to create BTY167 (pem1 / ::PEM1 pem2 /pem2 ::PEM2-SAT1). The SAT1 marker was removed by recombination from BTY167 to create the pem1 / ::PEM1 pem2 /pem2 ::PEM2 mutant (BTY169).
To create a repressible PEM1 mutant, SC5314 was transformed with linearized pYLC390 (KpnI-SacI) to yield a PEM1/pem1 -SAT1 strain (YLC394). The SAT1 marker was removed by recombination from YLC394 to yield a PEM1/pem1 strain (YLC401). YLC401 was then transformed with the PEM1 conditional expression vector pYLC414 (KpnI) to yield a pem1 /pem1 ::P MET3 -PEM1-SAT1 strain (YLC417).
To overexpress EPT1, SC5314 was transformed using linearized pBT11 (MscI) to create BTY88 (P ENO1 ::P ENO1 -EPT1). To knock out EPT1, pBT16 was linearized (KpnI, SacI) and transformed into SC5314 resulting in an EPT1/ept1 -SAT1 strain (BTY97). The SAT1 marker was removed by recombination from BTY97, resulting in BTY101 (EPT1/ept1 ). BTY101 was transformed with linearized pBT16 again to create the ept1 / -SAT1 strain, BTY104. The SAT1 marker was removed by recombination from BTY104 to create BTY108 (ept1 / ), so that a reintegrant strain could be produced. Two distinct types of reintegrant were produced: one in which the EPT1 gene was constitutively expressed, and another in which one allele of EPT1 was reintegrated into the EPT1 locus under its native promoter. For the first reintegrant, the overexpression cassette pBT11 was linearized (MscI) and transformed into BTY108, resulting in the ept1 / P ENO1 ::P ENO1 -EPT1 strain (BTY130). To reintegrate the gene under its native promoter and at the EPT1 locus, pBT53 was linearized using KpnI and SacI and subsequently transformed into BTY108 to yield BTY192 (ept1 / ::EPT1-SAT1). The SAT1 marker was then removed by recombination to yield BTY200 (ept1 / ::EPT1).
Growth Curves
To determine choline auxotrophy, strains were cultured overnight in liquid YNB medium [0.67% yeast nitrogen base containing ammonium sulfate (BD Difco, 291940), 2% dextrose], and then diluted to OD 600 nm = 0.1 in triplicate in fresh YNB (Styles, 2002) . Growth was measured at OD 600 nm every 2 h for 12 h or at other time points as indicated. To rescue choline auxotrophy YNB medium was supplemented with choline chloride (Fisher Scientific, O1972-250), glycerophosphocholine (Sigma-Aldrich, G5291-10MG), or lysophosphatidylcholine (Avanti Polar Lipids INC., 845875P).
Lipid Extraction and TLC
Candida albicans strains were cultured overnight in 5 mL YNB medium supplemented with 0.25 mM L-methionine/Lcysteine (represses PEM1 in pYLC417), and then diluted to an OD 600 nm = 0.4 in 25 mL of YNB with 0.25 mM L-methionine/L-cysteine or YNB supplemented with 1 mM choline chloride and 0.25 mM L-methionine/L-cysteine. Cultures were maintained at 30 • C for 12 h at 225 RPM and then transferred to 50 mL conical tubes and pelleted at 3000 RPM for 10 min. Pellets were lyophilized and weighed to normalize for the number of cells present. Following lyophilization, pellets were washed with 25 mL water and resuspended in 3 mL ethanol:water (4:1). Suspensions were heated in boiling water for 15 min and pelleted at 3,000 RPM for 10 min. The supernatant was transferred to new tubes and back extractions were completed twice using 1 mL of ethanol:water (4:1) following the above procedure. Lipids were dried under nitrogen gas and resuspended in chloroform:methanol (2:1). TLC plates were washed once with chloroform:methanol (2:1) and dried at 100 • C for 15 min. Lipid extracts were spot inoculated on TLC plates (Millipore, HX377581) and chloroform:ethanol:water:triethylamine (35:30:7:35) was used as a solvent system for separation (Chen et al., 2010) . Phospholipids were visualized under UV following treatment with primuline (Fisher Scientific, 8064-60-6).
Mouse Models
Outbred male ICR mice were obtained from Envigo for use in this study. C. albicans strains were cultured overnight in 50 mL YPD at 30 • C and 225 RPM. After approximately 16 h they were transferred to 50 mL Falcon tubes and centrifuged at 3,500 RPM for 5 min. The pellets were subsequently washed twice with 25 mL of water. Cells were counted via hemocytometer and diluted to 5 × 10 6 cells/mL unless otherwise noted. Mice were injected via the lateral tail vein with 0.1 mL of the C. albicans suspension. C. albicans suspensions were plated on YPD and incubated overnight at 30 • C to determine cell viability. Following infection, mice were monitored for signs of illness for 21 days and were sacrificed after succumbing to infection.
For experiments in which fungal burden was measured, mice were sacrificed 5 days post infection and kidneys were harvested. Kidneys were placed in 1 mL water within pre-weighed whirlpack bags and homogenized. Serial dilutions (10 −1 , 10 −2 , and 10 −3 ) were prepared in water, and 1 mL of each dilution was added to 1.1% Noble agar pours (3.5 mL) at 55 • C and poured onto YPD plates in duplicate for each dilution set. Plates were incubated at 30 • C overnight and colony forming unit (CFUs) were counted after 24 h.
Ethics Statement
All mouse model experiments in this study were performed under an animal protocol (0016-0714) that was approved by the University of Tennessee Institutional Animal Care and Use Committee (IACUC). We followed the ethical guidelines set forth by the National Institute of Health (NIH) for the ethical treatment of animals.
In vitro Cytotoxicity Assays
The FaDu oral epithelial cell line was used in this study (Martinez-Lopez et al., 2006) . Cells were routinely cultured in EBSS medium (Fisher Scientific, SH30024.01) with 10% fetal bovine serum (Fisher Scientific, BP1600-100) and 1% penicillin/streptomycin (Invitrogen, 15140-122) at 37 • C and 5% CO 2 . Prior to the cell killing assay, 5 × 10 5 cells/mL of FaDu cells were plated in a 24 well plate. For each C. albicans strain, 1 mL of FaDu cells was plated in triplicate. C. albicans strains were cultured overnight in 5 mL YPD, and then washed twice with sterile water. Cells were resuspended in 10 mL H 2 O and counted via hemocytometer. Solutions containing 2.5 × 10 6 cells/mL of each strain (MOI = 5) were made in EBSS supplemented with 2% Human Serum (MP Biomedicals, ICN2930149) and 1% penicillin/streptomycin.
Wells containing FaDu cells were aspirated and 1 mL of C. albicans cell suspensions were added to FaDu cells for co-incubation. In addition, the following control wells were included in triplicate: C. albicans alone, FaDu cells alone, medium alone, FaDu cells with lysis solution, and lysis solution with medium. Plates were centrifuged at 250 × g for 5 min and incubated for 4 h at 37 • C at 5% CO 2 . Following incubation, plates were spun at 250 × g for 5 min, and 50 µL of each supernatant were assayed for LDH release using the CytoTox 96 R Non-Radioactive Cytotoxicity Assay (Promega, G1780) using the manufacturer's protocol. Cytotoxicity was expressed as a relative percentage of the average wild type cytotoxicity, and three biological replicates were performed (each with technical replicates in triplicate).
PC Synthesis Assay
This procedure was done as previously described for a phosphatidylserine synthase assay with some changes (Bae- Lee and Carman, 1984; Cassilly et al., 2017) . The optimal PC synthesis assay mixture contained 50 mM Tris-HCl pH 7.5, 0.1% Triton X-100, 0.5 mM MnCl 2 and 0.1 mM DAG (Avanti Polar Lipids INC.) added as a suspension in 1% Triton X-100 and 0.5 mg protein in a total volume of 0.1 mL. The assay was performed by monitoring the incorporation of 0.5 mM cytidine diphosphocholine (Sigma-Aldrich) spiked with 10% by volume [14C] -methyl cytidine diphosphocholine (∼0.2 µCi) into the chloroform-soluble product at 37 • C for a predetermined amount of time. The reaction was terminated by the addition of 1 mL chloroform:methanol (2:1). Following this the reaction was extracted as previously described. Samples were fully dried in scintillation vials, 2.5 mL scintillation fluid was added to each vial, and they were measured with a liquid scintillation counter (Tri-Carb 2900TR).
In vivo PE Synthesis Assay
Cultures were grown to logarithmic phase at 30 • C in YNB in media supplemented with 100 µM choline chloride and 0.2 µCi/mL of [14C] ethanolamine. Phospholipids were isolated as described in Surlow et al. (2014) . Lipid extracts representing equivalent amounts of optical density units (ODUs) were spotted onto silica gel TLC plates and plates were developed in chloroform:ethanol:water:triethylamine (30:35:7:35). A Typhoon 8600 phosphorimager was used for visualization and quantitation of PC and PE regions of intensity (ROI).
Statistical Analyses and BLAST Parameters
All statistical analyses were carried out using GraphPad Prism (version 7.04). For mouse survival curves the logrank (Mantel-Cox) test was performed and for all other analyses unpaired t-tests between the indicated strains were used to determine statistical significance. For all analyses, p < 0.05 was used as a cutoff to determine statistical significance. To align protein sequences from S. cerevisiae to C. albicans, Basic Local Alignment Search Tool ProteinProtein (BLASTP) was used (NCBI, CGD). Sequences were obtained for S. cerevisiae S288C from the Saccharomyces Genome Database (SGD) and BLASTP was performed via the Candida Genome Database (CGD). The default settings were used to query assembly 22 of C. albicans SC5314 for hits. These settings included allowgaps = yes, gapext = 1, gapopen = 11, matrix = BLOSUM62.
RESULTS
Disruption of PEM1 and PEM2 Causes Choline Auxotrophy in C. albicans
To determine if CDP-DAG mediated PC biosynthesis is required for virulence in C. albicans, methylation of PE to PC was disrupted by constructing a pem1 / pem2 / knockout mutant using the SAT1 flipper method (Reuss et al., 2004) . The pem1 / pem2 / mutant is expected to be a choline auxotroph because it can only make PC from imported choline via the Kennedy pathway (Figure 1) . Therefore, growth of the pem1 / pem2 / mutant was observed for 48 h in minimal media (YNB) with or without 100 µM choline supplementation (Figure 2A) . Little growth occurred in minimal medium lacking choline, indicating that the pem1 / pem2 / mutant cannot synthesize PC efficiently due to disruption of the CDP-DAG pathway. Residual growth of pem1 / pem2 / may be due to the ability to store PC or choline within the cell. Addition of 100 µM choline or reintegration of the methyltransferase genes (pem1 / ::PEM1 pem2 / ::PEM2 strain) restored growth to wild-type levels, which indicates that exogenous choline can be used to synthesize PC via the Kennedy pathway. In fact, choline levels as low as 10 µM also restored growth to nearly wild-type levels ( Figure 2B ). Choline is found at ∼11 µM in rodent serum (Klein et al., 1993) .
To further investigate the ability of C. albicans to acquire choline from other exogenous sources we tested several cholinecontaining compounds that are commonly found in human and rodent tissues/serum, including lysophosphatidylcholine (LPC) and glycerophosphocholine (GPC), (Croset et al., 2000; Ilcol et al., 2005) to determine if they could also restore growth. LPC is as high as 450 µM in rat serum (Suarez-Garcia et al., 2017) and GPC is as high as 4.5 µM, but GPC can be over 1 mM in homogenized brain tissue and approximately 270 µM/g protein in homogenized kidney tissue (Bauernschmitt and Kinne, 1993; Klein et al., 1993) . The growth of the pem1 / pem2 / mutant was restored to the wild type level in minimal media when supplemented with either 100 µM GPC or LPC, and was restored to nearly wild-type levels even at 10 µM (Figures 2C,D) .
To confirm that the pem1 / pem2 / mutant's lack of growth in choline-free media correlates with loss of PC synthesis, total lipids were extracted from cells growing in minimal medium lacking a source of choline, and analyzed by thin layer chromatography (TLC) (Supplementary Figure S1) . While wild type C. albicans was able to produce PC regardless of supplementation, the pem1 / pem2 / mutant failed to produce PC unless supplemented with choline.
Single mutants for both PEM1 and PEM2 were also tested for PC synthesis. For PEM1, a pem1 /PEM1::P MET3 -PEM1 conditional knockout was used, and for PEM2 a pem2 / conventional knockout was made. Both were cultured in YNB with or without 1 mM choline (Supplementary Figure S1) . In addition, the YNB media included 0.25 mM cysteine/methionine FIGURE 2 | The pem1 / pem2 / mutant is a choline auxotroph. (A) Wild type, pem1 / pem2 / , and pem1 / ::PEM1 pem2 / ::PEM2 strains were grown overnight in minimal media, diluted to an OD 600 nm = 0.1, and then cultured for 48 h in minimal media, with or without 100 µM choline (CHO). Wild type and pem1 / pem2 / were also cultured for 48 h in minimal media, with or without varying concentrations of (B) choline (CHO), (C) glycerophosphocholine (GPC), or (D) lysophosphatidylcholine (LPC). These assays were performed with three biological replicates.
to shut off expression of PEM1 in the pem1 /PEM1::P MET3 -PEM1 strain. The pem1 /PEM1::P MET3 -PEM1 strain was fully capable of PC production even in the absence of choline when methionine/cysteine were present, but the pem2 / mutant failed to produce PC unless supplemented with choline and there was an increase in the intermediate product monomethylethanolamine. This resembles S. cerevisiae, in which PEM2 has overlapping substrate specificity and can methylate PE (Preitschopf et al., 1993; Henry et al., 2012) . This also indicates that Pem1 cannot efficiently methylate the intermediate products monomethylethanolamine or dimethylethanolamine to PC on its own.
PE From the CDP-DAG Pathway Accumulates in the pem1 / pem2 / Mutant
If PE methylation to PC is blocked, it is expected that PE will accumulate in the cell and PC from this pathway will decrease. To test this, [14C] ethanolamine radiolabeling assays of whole cells were performed using the pem1 / pem2 / mutant. This experiment measures the accumulation of PE that is derived from the Kennedy pathway. There was an approximate 1.44-fold increase in radiolabeled PE in pem1 / pem2 / mutants as compared to the wild type ( * * * p < 0.001) (Figure 3) and little or no PC was detected. Thus, blockage of PE methylation results in the expected depletion of labeled PC and a buildup of labeled PE. When the methyltransferases are reintegrated into the mutant, statistically significant decreases in PE radiolabel accumulation and concurrent increases in PC radiolabel accumulation are measured relative to the mutant ( * p < 0.05). These data do not measure the total PE and PC in the cells, as the phospholipid pools produced by the CDP-DAG pathway for PE or the Kennedy pathway for PC are unlabeled (Figures 1, 3) , but the data do reveal that blockage of the CDP-DAG pathway at this point increases PE and decreases PC specifically generated from imported ethanolamine.
Blockage of PC Synthesis by the PE Methyltransferase Mutant pem1 / pem2 / Results in Hypervirulence
Choline, GPC, and LPC can fully support growth of pem1 / pem2 / mutants in vitro (Figure 2) . These compounds are all found in the host, and therefore can be used to make PC by pathways that are alternatives to the CDP-DAG pathway, such as the Kennedy pathway (Figure 1) . However, it was still possible that loss of PEM1 and PEM2 would affect virulence, so the mutants were tested in a mouse model of systemic infection. Outbred ICR mice were infected with 3 × 10 5 cells each of either wild type (n = 35), pem1 / pem2 / (n = 25), or pem1 / ::PEM1 pem2 / ::PEM2 (n = 10) via the tail vein. The pem1 / pem2 / strain is fully virulent (Figure 4) , indicating that PC biosynthesis by the CDP-DAG pathway is not required for full virulence, as the Kennedy pathway can synthesize enough PC in vivo to support virulence using choline obtained from the host.
Moreover, mice infected with the pem1 / pem2 / mutant succumb to infection more rapidly than those infected with wild type ( * * p < 0.01) (Figure 4) . This was unexpected, and we hypothesized that the pem1 / pem2 / mutant might be more virulent because the blockage of PC biosynthesis by the CDP-DAG pathway leads to increased PE, as seen in vitro (Figure 3) . This could be because a block of the CDP-DAG pathway upregulates an alternative PE synthesis pathway, such as the Kennedy pathway. Alternatively, there may just be a buildup FIGURE 3 | The pem1 / pem2 / mutant cannot produce PC via the CDP-DAG pathway. Strains were cultured in the presence of [14C] ethanolamine and incorporation of the radiolabel into PE and PC was quantified using thin-layer chromatography (TLC) of extracted lipids ( * * * p < 0.001, * p < 0.05; unpaired t-test compared to wild-type). This assay was performed with biological replicates in triplicate.
FIGURE 4 | The pem1 / pem2 / mutant is hypervirulent. Mice were infected via the lateral tail vein with 3 × 10 5 wild type (WT), pem1 / pem2 / , or pem1 / ::PEM1 pem2 / ::PEM2 cells. Mice infected with the pem1 / pem2 / mutant succumb to infection more rapidly than those infected with wild type C. albicans [ * * p < 0.01 compared to wild-type; log-rank (Mantel-Cox) test]. The number of mice representing each strain is shown in parenthesis beside each strain.
of PE as it cannot be methylated. In either case, this may have a downstream effect on virulence. If so, then overexpression of the Kennedy pathway (overexpression of PE synthesis enzymes by an alternative means), should increase virulence in a similar manner.
In Contrast to S. cerevisiae, in C. albicans One Enzyme, Ept1, Catalyzes the Final Step for Both PE and PC Biosynthesis in the Kennedy Pathway
The Kennedy pathway can use exogenous choline and ethanolamine from the environment to form PC and PE, respectively, and it also makes PC from internal stores of choline that have been released by phospholipase activity (Dowd et al., 2001; Fernandez-Murray et al., 2009 ). The current model for the C. albicans Kennedy pathway is inferred from that characterized in baker's yeast (Figure 1) . In S. cerevisiae there are two branches of the Kennedy pathway; the CDPethanolamine and CDP-choline branches (Gibellini and Smith, 2010) (Figure 5A ). Each branch catalyzes analogous reactions to convert ethanolamine or choline into PE or PC, respectively. To begin synthesis of either PE or PC, ethanolamine or choline are imported into the cell by the ethanolamine/choline importer Hnm1 (Nikawa et al., 1986 (Nikawa et al., , 1990 . These precursors are then phosphorylated by either ethanolamine (Eki1) or choline (Cki1) kinase to form phosphoethanolamine (PEtn) or phosphocholine (P-Cho), respectively (Gibellini and Smith, 2010) . P-Etn and P-Cho are used to form the highenergy intermediates CDP-ethanolamine and CDP-choline by the ethanolamine and choline cytidyltransferases, Ect1 and Pct1, respectively (Gibellini and Smith, 2010) . Finally, diacylglycerol is condensed with CDP-ethanolamine by Ept1 to form PE, or CDP-choline by Cpt1 to form PC, with the release of CMP in both cases (Gibellini and Smith, 2010) .
The two S. cerevisiae enzymes that represent each step of the Kennedy pathway (one from each branch, Figure 5A ) share high sequence identity. For example, when searching the C. albicans protein database in the Candida Genome Database (CGD) with the Basic Local Alignment Search Tool (BLAST) using the S. cerevisiae Eki1 sequence as a query, hits are given for both the C. albicans Eki1 (C7_01320W/orf19.6912) and Cki1 (C3_05300C/orf19.6966) sequences (e-values of 6e-7 and 8e-87, respectively). The same is true for S. cerevisiae Cki1. Thus, this holds true for the enzymes in the first two steps proposed model for C. albicans Kennedy pathway. Etn, ethanolamine; Cho, choline; P-Etn, phosphoethanolamine; P-Cho, phosphocholine; CDP-Etn, cytidinediphosphoethanolamine; CDP-Cho, cytidinediphosphocholine.
of the Kennedy pathway. However, we recovered only one protein sequence when we used BLAST to search CGD with the S. cerevisiae Ept1 or Cpt1 protein sequences. For either S. cerevisiae protein, a single C. albicans protein is revealed that is designated as Ept1 (C7_02690C/orf19.3695), (e-value of 3e-114 for Ept1 and 7e-111 for Cpt1). We hypothesized that C. albicans differs from S. cerevisiae in that it uses a single phosphotransferase (C. albicans Ept1) to catalyze the addition of both CDP-ethanolamine and CDP-choline to DAG to make PE and PC, respectively ( Figure 5B) . If so, blocking this step of the pathway would impede Kennedy pathway mediated synthesis of both PE and PC. Alternatively, overexpressing it may increase synthesis of both PE and PC as well.
In order to determine if Ept1 alone catalyzes the final step of both branches of the Kennedy pathway in C. albicans, an ept1 / knockout strain was generated using the SAT1 flipper method (Reuss et al., 2004) . In addition, EPT1 was cloned into an overexpression vector under the control of the strong, constitutive ENO1 promoter in order to create a P ENO1 -EPT1 overexpression plasmid. This P ENO1 -EPT1 plasmid was integrated into wild-type C. albicans. In addition, reintegrants were made for ept1 / in which one allele of EPT1 was expressed at its native locus and under control of its native promoter or the P ENO1 -EPT1 plasmid was used to reintegrate the gene.
To determine if these alterations in EPT1 affected PC synthesis from its precursors CDP-choline and diacylglycerol (DAG), as predicted, a CDP-cholinephosphotransferase assay was performed on membranes isolated from each strain. Membranes were isolated from the strains and incubated with [14C] CDPcholine and DAG, and the level of [14C] PC synthesized was measured. Disruption of EPT1 resulted in a total loss of PC synthesis, while overexpression of EPT1 in wild-type or ept1 / resulted in twice the level of [14C] PC as found in wild-type ( Figure 6A , * * p < 0.01). Thus, Ept1 is solely responsible for catalyzing PC synthesis from CDP-choline and DAG.
Due to difficulty in obtaining radiolabeled [14C] CDPethanolamine, the role for C. albicans Ept1 in PE synthesis was tested by measuring synthesis of [14C] PE from [14C] ethanolamine in whole cells. Each strain was cultured in minimal (YNB) media supplemented with [14C] ethanolamine, and lipids were extracted (Surlow et al., 2014) , separated by TLC, and quantified to measure incorporation of the radiolabel into PE (Figure 6B, * p < 0.05). Confirming our hypothesis, the ept1 / strain does not incorporate a detectable amount of radiolabel into PE. In contrast, the P ENO1 -EPT1 strain incorporates increased radiolabel into PE. Finally, the ept1 / mutant transformed with P ENO1 -EPT1 or EPT1 on its native promoter has a restored ability to incorporate the radiolabel into both phospholipids (Figures 6A,B) . Thus, EPT1 solely catalyzes the final step of both the CDP-choline and CDPethanolamine branches of the Kennedy pathway in C. albicans ( Figure 5B) .
Overexpression of EPT1 Results in Hypervirulence in the Mouse Systemic Infection Model
Given that overexpression of EPT1 increases PE/PC synthesis by the Kennedy pathway, we wanted to determine if this would also cause hypervirulence as observed for pem1 / pem2 / , which also accumulates PE (Figure 3) . Therefore, wild-type and P ENO1 -EPT1 strains were tested in the mouse model of systemic candidiasis. Mice infected with P ENO1 -EPT1 C. albicans succumbed to infection more rapidly than those infected with wild type ( * * p < 0.01) ( Figure 7A) . Thus, the P ENO1 -EPT1 and pem1 / pem2 / mutants both accumulate PE and exhibit hypervirulence. CDP-choline incorporation into PC was measured. Enzyme activity was measured as counts per minute per milligram of protein, and is expressed as a percentage of wild-type ( * * p < 0.01; unpaired t-test compared to wild-type, WT). (B) Each strain was cultured in the presence of [14C] ethanolamine and incorporation of the radiolabel into PE was quantified by phosphorimager from thin-layer chromatography ( * p < 0.05; compared to wild-type, WT, by the unpaired t-test). Each of these assays was performed with three biological replicates.
FIGURE 7 | Overexpression of EPT1 causes hypervirulence. (A) Mice infected with P ENO1 -EPT1 overexpression strain (n = 14) succumb to infection more rapidly than the wild type (WT, n = 15) [ * * p < 0.01; compared to WT, log-rank (Mantel-Cox) test]. Mice infected with the isogenic ept1 / mutant do not differ significantly from those infected with wild type C. albicans (n = 10). The n-values for wild-type and P ENO1 -EPT1 were derived from three separate experiments, and those for ept1 / were derived from two separate experiments. (B) Mice infected with ept1 / have a decreased kidney fungal burden 5 days post infection compared to those infected with the wild type ( * p < 0.05; unpaired t-test, n = 15 mice per strain). Mice infected with the ept1 / P ENO1 -EPT1 reintegrant were not significantly different than those infected with the wild type. Experiments were performed three times using five mice per strain and kidney homogenates were plated with two technical replicates for reproducibility. (C) Expression level of C. albicans EPT1 affects cytotoxicity in co-culture with human epithelial cells in vitro. The P ENO1 -EPT1 overexpression strain has increased cytotoxicity ( * p < 0.05; unpaired t-test) compared to wild type, whereas ept1 / has decreased cytotoxicity ( * * p < 0.01). The ept1 / P ENO1 -EPT1 reintegrant is not significantly different than wild type for cytotoxicity. Biological replicates were performed in triplicate and technical replicates were also performed in triplicate (n = 9 total replicates per strain).
We wanted to determine if this hypervirulence would correlate with increases in kidney fungal burden. Outbred ICR mice (Envigo) were infected with 5 × 10 5 cells of the wild-type and P ENO1 -EPT1 strains. Five days post infection, the mice were necropsied and kidneys were harvested to determine fungal burden. Mice infected with the P ENO1 -EPT1 overexpression strain exhibited an average increase in fungal burden of 38.1% when compared to mice infected with wild type C. albicans, however, this difference was not statistically significant ( Figure 7B , * p = 0.1885).
Disruption of EPT1 Results in a Decrease in Kidney Fungal Burden in Mice
As EPT1 is necessary for PE and PC synthesis through the Kennedy pathway, and its overexpression increases virulence, we tested an ept1 / mutant in the mouse model to determine if it exhibits decreased virulence. For survival curves in the systemic infection model there was not a significant decrease in virulence for the ept1 / strain compared to wild type ( Figure 7A ). However, it should be noted that mice infected with the ept1 / strain began to succumb to infection at 11 days post infection, which is slightly delayed compared to those infected with the wild-type (which begin to succumb to infection at 7 days post infection), which may indicate a modest, although not statistically significant, decrease in virulence. Although there was not a statistically significant difference in survival curves, mice infected with the ept1 / mutant had a significant average decrease in kidney fungal burden of 44.97% as compared to the wild type ( * p < 0.05) (Figure 7B ). This decrease in fungal burden may correlate with the slight delay seen in survival curves for mice infected with the ept1 / strain. Conversely, mice infected with the reintegrant ept1 /ept1 ::P ENO1 -EPT1 strain did not exhibit any significant differences in fungal burden compared to mice infected with wild type C. albicans.
EPT1 Expression Affects Cytotoxicity of C. albicans Against Epithelial Cells
The mechanism by which EPT1 impacts virulence is unclear, as there are no clear impacts on growth rate in growth curves (data not shown). Thus, we examined another virulence factor, which is the ability of C. albicans to damage epithelial cells. This can be assessed by measuring the release of the cytoplasmic enzyme lactase dehydrogenase (LDH) from host cells. In order to measure cytotoxicity of each mutant compared to wild-type, 2.5 × 10 6 C. albicans cells were co-cultured with human oral epithelial cells (FaDu cell line). A CytoTox 96 R cytotoxicity assay kit (Promega) was used to quantify the release of LDH after 4 h. There was a statistically significant decrease in cytotoxicity of the ept1 / mutant as compared to the wild type ( * * p < 0.01) ( Figure 7C) . Conversely, the P ENO1 -EPT1 overexpression mutant has increased cytotoxicity compared to the wild type ( * p < 0.05) ( Figure 7C ). The ept1 / P ENO1 -EPT1 reintegrant does have a modest increase in cytotoxicity versus the wild type, but it is not statistically significant ( Figure 7C ).
DISCUSSION
In a previous communication we demonstrated that the synthesis of phospholipids via the CDP-DAG pathway is absolutely required for Candida albicans to be able to cause disease in the mouse model of systemic infection (Chen et al., 2010) . The phospholipids produced in this pathway specifically are PS, PE, and PC (Figure 1) . Blocking synthesis of PS or PE by disrupting the PS synthase (cho1 / mutant) or both PS decarboxylases (psd1 / psd2 / mutant) results in avirulence (Chen et al., 2010) . Although the full mechanism is not clear (Davis et al., 2018) , PS and PE synthesis by the CDP-DAG pathway clearly play a crucial role in virulence. However, at the outset of this study the role of PE's downstream product, PC, was less clear. In addition, no prior studies have directly evaluated the role of the Kennedy pathway with regard to virulence in C. albicans.
Increased PE in Two Different Pathways Correlates With Hypervirulence
To determine if PC was important for the ability to cause disease, we blocked CDP-DAG mediated PC biosynthesis by the pem1 / pem2 / mutation. Systemic infections carried out in mice revealed that this mutation did not block virulence, but instead mice infected with the pem1 / pem2 / mutant succumb to infection more rapidly than those infected with wild-type (Figure 4) .
The pem1 / pem2 / mutation causes a loss of PC synthesis by methylation of PE, but simultaneously leads to a build-up of PE (Figure 3) . Synthesis of PE has been shown to be required for virulence (Chen et al., 2010; Davis et al., 2018) , which suggests the possibility that increased PE might lead to greater virulence. Therefore, we increased PE synthesis through the Kennedy pathway by overexpressing EPT1 (Figure 6) , and this led to hypervirulence as well ( Figure 7A ). This suggests that increased PE synthesis causes hypervirulence, however, it should be noted that overexpression of EPT1 also causes increased PC synthesis.
We favor increased synthesis of PE rather than PC as the explanation for hypervirulence since PE builds up, but PC goes down in the hypervirulent pem1 / pem2 / mutant (Figure 3) . Thus, the common phospholipid to increase in both pem1 / pem2 / and P ENO1 -EPT1 (Figures 3, 6) is PE. Furthermore, PE synthesized from either the CDP-DAG or Kennedy pathways can support virulence (Chen et al., 2010; Davis et al., 2018) . Thus, taken altogether, these data suggest PE is the primary phospholipid influencing virulence. However, the mechanism by which elevated PE causes virulence is not clear at this point. We do note that increased EPT1 correlates with increased damage of epithelial cells, and although modest, this assay is measuring only short term (4 h) damage, so increased damage over time (∼10 days) may accumulate leading to more rapid terminal infection. However, the full mechanism by which increased virulence is mediated is unknown.
EPT1 Is Required for Full Virulence During Systemic Infections
Overexpression of EPT1 leads to hypervirulence, but we also wanted to determine whether the Kennedy pathway is required for full virulence in C. albicans, as this pathway is present in a variety of eukaryotic pathogens and is required for virulence in some (Gibellini et al., 2009 ). Furthermore, it has been demonstrated that blocking the ability of C. albicans to import glycerophosphocholine (GPC), an intermediate metabolite that may be shunted into the Kennedy pathway, attenuates virulence in the mouse model of systemic infection (Bishop et al., 2013) . Until now, no virulence studies have been performed on the Kennedy pathway in C. albicans, and so it has also remained unknown whether this pathway is redundant in C. albicans, or if it is specifically required for growth in the host.
We found that disruption of EPT1 caused a modest decrease in kidney fungal burden (Figure 7B ), but not a significant increase in mouse survival ( Figure 7A ). This modest decrease in fungal burden might help explain the modest increase in the time in which mice begin to succumb to infection in the ept1 / mutant (11 days) compared to wild-type (7 days) (Figure 7A) , however, the overall difference in curves was not statistically significant, so the modest decrease in fungal burden does not appear to have a large impact on overall virulence. The decrease in kidney fungal burden also correlated with a modest decrease in damage to epithelial cells ( Figure 7C ). Thus, it is possible that the ept1 / mutant is unable to damage host cells as well as wild-type C. albicans, and this could help explain the loss of fungal burden. Also, it is not entirely clear whether the effect is related to PE or PC, as Ept1 synthesizes both in C. albicans.
C. albicans Ept1 Synthesizes Both PE and PC in the Kennedy Pathway
Prior to this study the model for the Kennedy pathway in C. albicans was based entirely on that elucidated for S. cerevisiae. However, we found that while all the enzymes involved in the first two steps of either PE or PC biosynthesis had homologs in C. albicans, only one enzyme for the last step of synthesis was found in C. albicans: Ept1. Given the results of the homology search and the fact that there is some overlap in substrate specificity between EPT1 and PCT1 in S. cerevisiae (Gibellini et al., 2009) , we hypothesized that this enzyme was responsible for both PE and PC biosynthesis in C. albicans. This was tested using [14C] radiolabeling. Our findings are that the knockout cannot incorporate radiolabeled precursors into either PE or PC, and that when the gene is overexpressed an increased amount of the radiolabeled precursors are incorporated into PE and PC. This indicates that Ept1 is the only enzyme that catalyzes this reaction in C. albicans, and we can therefore block the Kennedy pathway by knocking out EPT1 and increase phospholipid synthesis via this pathway by overexpressing EPT1.
We do not yet fully understand how the Kennedy pathway influences virulence, but the ability to modulate virulence in either direction using EPT1 expression levels indicates that this is an important pathway for controlling the pathogenicity of this fungus.
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